Veeda opens Ph I unit in Malaysia

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical trial Contract research organization

India’s Veeda Clinical Research has set up a Phase I unit in Malaysia, joining the growing list of contract research organisations (CRO) attracted to the country.

The new 28 bed unit, which is located at Ampang Hospital in the capital Kuala Lumpur, will provide support for early-stage clinical development projects, the first of which are due to start in the next few months.

Veeda set up the facility in collaboration with a team from Malaysian Ministry of Health which, according to group medical director Maurice Cross, was critical to its successful completion.

Without the help and support of Tan Sri Ismail Merican, the then Medical Director General, Dr Lim Tek Ono and Dato’ SC Teoh in the early days this project would never have got started.”

This was echoed by Goh Pik Pin from the Ministry of Health, who added that: “It is very difficult, sometimes, to integrate the approaches of private CROs and Governmental agencies but…we have succeeded and now look forward to beginning a planned series of studies intended to stretch and develop the Unit's capabilities."

Malaysia pharma development

The Malaysian Government has courted the contract research sector in the last few years in an effort to strengthen its clinical infrastructure in

This has seen, since 2009, companies such as Kendle, Novotech​, Quintiles​ and, most recently, Siro Clinpharm​ set up a variety of early and late-stage clinical research capabilities in the country.

Veeda, like all of the other recent additions to the Malaysian research sector, cited the rules that govern clinical trials in the country as particularly attractive and a key driver for the investment;.

It said that: “Regulatory and start-up times in Malaysia are very favourable even when compared with the Western Countries and are far faster than many evolving countries.”

The firm also said that the National Disease Registry as a key factor in the decision, explaining that it makes the identification of patient populations “especially easy and efficient​."

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more